Tango Therapeutics, Inc.
TNGX
Kedudukan dalam Saham
#4545
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Harga Saham
$27.18
Disegerakkan terakhir: 2026-07-31
Modal Pasaran
$3.38B
Perubahan (1 hari)
-1.41%
Perubahan (1 tahun)
202.34%
Negara
US
Perdagangan Tango Therapeutics, Inc. (TNGX)
Kategori
Healthcare
Hasil untuk Tango Therapeutics, Inc. (TNGX)
Hasil pada Jun 2026 TTM: $53.81M
Menurut laporan kewangan terkini daripada Tango Therapeutics, Inc., hasil semasa syarikat (TTM) ialah $53.81M. Pada tahun 2023, syarikat memperoleh hasil sebanyak $36.53M peningkatan berbanding hasil pada tahun 2022 iaitu $24.86M. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Tango Therapeutics, Inc. dari 2019 hingga 2026
Hasil pada akhir setiap tahun
| Tahun | Hasil | Ubah |
|---|---|---|
| 2026 (TTM) | $53.81M | 27.91% |
| 2024 | $42.07M | 15.17% |
| 2023 | $36.53M | 46.93% |
| 2022 | $24.86M | -32.89% |
| 2021 | $37.04M | 383.83% |
| 2020 | $7.66M | -68.94% |
| 2019 | $24.65M | 0.00% |
Hasil untuk syarikat atau pesaing serupa
| Syarikat | Hasil | Perbezaan Hasil | Negara |
|---|---|---|---|
| $12.62B | 23,360.44% |
US
|
|
| $2.23B | 4,040.42% |
US
|
|
| $15.74B | 29,158.57% |
AU
|
|
| $6.02B | 11,089.70% |
NL
|
|
| - | - |
CH
|
